Author: Farina, Nicola; Ramirez, Giuseppe A.; De Lorenzo, Rebecca; Di Filippo, Luigi; Conte, Caterina; Ciceri, Fabio; Manfredi, Angelo A.; Rovere-Querini, Patrizia
Title: COVID-19: Pharmacology and kinetics of viral clearance Cord-id: 7vhb4luq Document date: 2020_8_3
ID: 7vhb4luq
Snippet: Coronavirus Disease 2019 (COVID-19) is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of COVID-19 is broad and varies from mild to severe forms complicated by acute respiratory distress and death. This heterogeneity might reflect the ability of the host immune system to interact with SARS-CoV2 or the characteristics of the virus itself in terms of loads or persistence. Information on this issue might derive from interventional
Document: Coronavirus Disease 2019 (COVID-19) is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of COVID-19 is broad and varies from mild to severe forms complicated by acute respiratory distress and death. This heterogeneity might reflect the ability of the host immune system to interact with SARS-CoV2 or the characteristics of the virus itself in terms of loads or persistence. Information on this issue might derive from interventional studies. However, results from high-quality trials are scarce. Here we evaluate the level of evidence of available published interventional studies, with a focus on randomised controlled trials and the efficacy of therapies on clinical outcomes. Moreover, we present data on a large cohort of well-characterized patients hospitalized at a single University Hospital in Milano (Italy), correlating viral clearance with clinical and biochemical features of patients.
Search related documents:
Co phrase search for related documents- absolute number and low baseline: 1
- absolute number and low mortality: 1, 2, 3
- absolute number and low quality: 1
- absolute number and lung damage: 1
- absolute number and lung inflammation: 1
- absolute number and lung inflammatory: 1
- active termination and lopinavir ritonavir: 1, 2
- acute ards respiratory distress syndrome and long significant: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lopinavir hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute ards respiratory distress syndrome and lopinavir ribavirin: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lopinavir ribavirin interferon: 1
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute ards respiratory distress syndrome and lopinavir ritonavir ribavirin: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lopinavir ritonavir ribavirin interferon: 1
- acute ards respiratory distress syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and low baseline: 1
- acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute ards respiratory distress syndrome and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
Co phrase search for related documents, hyperlinks ordered by date